NCT05794672 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

July 8, 2023

Study Completion Date

July 8, 2023

Conditions

Healthy Subjects (Indication: Asthma)

Interventions

DRUG

Elarekibep

Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.

DRUG

Placebo

Subjects will receive single or multiple inhaled doses A, B or C.

Trial Locations (1)

Research Site, Harrow